Latest LLYC news and sentiment

Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?

Eli Lilly LLY and Johnson & Johnson JNJ are two leading U.S.-based healthcare companies with strong positions across the pharmaceutical and biotech industries. Both companies have significant exposure to oncology, immunology and neuroscience. J&J's business is more diversified, with treatments targeting cardiovascular and metabolic conditions, pulmonary hypertension and infectious diseases, along with a sizable medical devices operation. Lilly, meanwhile, has built a leading position in cardiometabolic care, fueled by its GLP-1 portfolio, with Mounjaro and Zepbound serving as major growth engi

Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.

Currently trading at around $1,160 per share, Eli Lilly (NYSE: LLY) has one of the highest stock prices in the S&P 500. While fractional stock trading means a high absolute share price doesn't hinder performance as much as it used to, there are other reasons a high price might. It may make sense for Eli Lilly to split its stock soon, something it hasn't done in nearly 30 years. The company has yet to officially announce any sort of stock split plans. However, don't assume that, if it happens, a split will serve as a game changer for what is the most widely followed of the GLP-1 stocks. Missed

Lilly Launches Foundayo in the UK as NICE Review Continues

Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company's oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch gives Lilly (NYSE:LLY) an oral alternative to its injectable treatments, but access through England's state-run National Health Service will depend on a separate review.Is Eli Lilly and Company (LLY) The Best Robinhood Stock to

Lilly looks beyond obesity with $2.88B autoimmune buyout

Eli Lilly (LLY) has spent the last two years as the company everyone points to when they talk about weight-loss drugs. That reputation made it the most valuable pharmaceutical company in the world. It also created a problem the company now seems eager to solve. On August 31, Lilly agreed to buy Merida Biosciences for up to $2.88 billion in cash. This deal expands Lilly's work into autoimmune diseases, which is a different field from the weight-loss and diabetes shots that made the company famous. For anyone holding LLY shares or thinking about buying in, this deal tells you something useful ab

Eli Lilly and Company: Konsensus der Analysten und Kursziel | 858560 | US5324571083

Lilly's African Mounjaro Push Starts at 1.25% of Quarterly Sales

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the diabetes and obesity-drug powerhouse, traded at $1,154.24 Thursday as Mounjaro secured a concrete African growth target. Distributor Aspen Pharmacare expects regional sales to break 2 billion rand, or roughly $124 million, in the year ending June 2027. Warning! GuruFocus has detected 7 Warning Sign with CVX. Is LLY fairly valued? Test your thesis with our free DCF calculator. South Africa is already moving fast. The country's GLP-1 market nearly doubled to 2.8 billion rand over the past year, while Mounjaro's share rocketed fr

Eli Lilly Just Announced a Major Acquisition. Here's What It Means.

This week, Eli Lilly (NYSE: LLY) announced a deal that will add to its already formidable drug pipeline. The drug maker said it will acquire Merida Biosciences for $2.9 billion, beefing up its pipeline of potential treatments for autoimmune and allergic diseases. Merida is developing drugs that selectively degrade pathogenic autoantibodies, disease-causing agents that underlie a host of immune-mediated conditions. Many other autoimmune therapies broadly suppress the entire immune system, whereas the therapies Merida is working to bring to market target only specific pathogens without disruptin

Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity

Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion to expand its immunology pipeline. Merida's lead candidate, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease. Eli Lilly's GLP-1 strength continues to support growth, but valuation, payer coverage and expectations remain important risks. On Aug. 31, Eli Lilly & Co. (NYSE: LLY) announced its intention to acquire Merida Biosciences for $2.875 billion. The acquisition will expand Lilly's portfolio for serious autoi

This New Zepbound Study Could Be Great News for Eli Lilly Investors

Eli Lilly (NYSE:LLY) has performed well in recent years thanks to its strong position in the GLP-1 market. However, it has encountered some obstacles, one of which is spotty (at best) insurance coverage for Zepbound, its GLP-1 weight-loss medication. The drug's out-of-pocket monthly price is high, and the fact that a significant portion of patients can't rely on insurance to cover the cost has arguably limited its potential. But what if Eli Lilly could make progress in expanding insurance coverage for Zepbound? The company recently released results from a real-world study that could help it ma

Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal

Eli Lilly LLY announced that it has entered into a definitive agreement to acquire clinical-stage biotech Merida Biosciences in an all-cash transaction for up to $2.875 billion. Though the deal includes an upfront payment as well as additional payments contingent on achieving specified development and regulatory milestones, neither company provided a breakdown of the consideration. Upon completion of this acquisition, Lilly will add Merida's antibody-engineering platform as well as a pipeline of biologics designed to target a range of immune-mediated conditions. This includes the lead drug, ME

Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference

INDIANAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 1:50 p.m. Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.

Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal

Lilly's $2.88 Billion Immunology Deal Starts in Phase 1

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the pharmaceutical powerhouse, agreed to acquire Merida Biosciences for up to $2.875 billion in cash, adding another high-risk, high-upside immunology bet. Reuters reported the deal Monday. Lilly shares fell approximately 1.7% to $1,154.73, the price shown in the chart. Warning! GuruFocus has detected 9 Warning Signs with AFRM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The official agreement includes an undisclosed upfront payment, with the rest dependent on future milestones. Merida's main asset is MER5

Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong?

Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based payments. The deal is expected to close in the fourth quarter of 2026. The acquisition expands Lilly's immunology pipeline and gives it access to Merida's antibody-engineering platform, which is designed to selectively eliminate disease-causing autoantibodies while preserving normal immune function. Merida's lead candidate, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease (TED). Early data showed

A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today

Eli Lilly & Co_ by Tada Images via Shutterstock Eli Lilly (LLY) shares are in the spotlight on Monday after the pharmaceutical behemoth announced a $2.88 billion acquisition of Merida Biosciences. The all-cash acquisition of the biotechnology company marks LLY's latest move to expand its drug pipeline. Note that Eli Lilly stock has been a blockbuster investment in recent months, currently up roughly 35% versus its year-to-date low in late April. More News from Barchart Dear Sandisk Stock Fans, Mark Your Calendars for August 31 Dear Palantir Stock Fans, Here's What Maven's Billion-Dollar ARR Me

Lilly Is Bigger Than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions. Continue Reading

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock.

Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions. Continue Reading

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity

At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed in the TOGETHER-PsO and TOGETHER-PsA trials Systemic inflammation and metabolic outcomes continued to improve or were sustained at one year with Taltz and Zepbound compared to Taltz alone in pre-specified, exploratory endpoints Data from first-of-their-kind studies contribute to the understanding of immunometabolic health INDIANAPOLIS, Aug. 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile Acquisition strengthens Lilly's immunology capabilities and its opportunity to elevate the standard of care for immune-mediated conditions with high unmet need INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Merida Biosciences, Inc. (Merida),

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly (NYSE: LLY) was the second company to market a GLP-1 drug. That's important to keep in mind as you look at the competitive landscape for this new class of weight-loss drugs. In some ways, investors do need to worry that companies like Amylyx (NASDAQ: AMLX) are developing next-generation GLP-1 drugs. New drugs are a threat to Eli Lilly's business. But Eli Lilly isn't ignorant of that threat. Here's what you need to know. Novo Nordisk drops the ball Novo Nordisk (NYSE: NVO) was the first to market with a GLP-1 weight-loss drug. It faced production issues and, when Eli Lilly's Mounjaro